<h1 class="pgc-h-arrow-right" data-track="1" > ethyl 4-chloroacetoacetate is tightly supplied</h1>
Ethyl 4-chloroacetoacetate CAS number 638-07-3, molecular formula C6H9ClO3, the appearance of colorless to light yellow liquid, is an important pharmaceutical, pesticide intermediate, mainly synthesize cardiovascular and cerebrovascular diseases high-efficiency drugs atovata calcium, oxiracetam, etc., but also the synthesis of the third and fourth generation of cephalosporin APIs. Ethyl 4-chloroacetoacetate has many synthetic routes, mainly made of divinylone, chlorine, dichloromethane, ethanol and other raw materials. In addition, Jiangsu Hengan Chemical Co., Ltd. disclosed a method for preparing ethyl 4 chloroacetoacetate, which is based on ethyl acetate and sulfonyl chloride as raw materials.
In recent years, with the development of the aging of the Chinese population and the improvement of the living conditions of the people, the number of people with hypertension, diabetes, smoking, obesity and other groups has increased, making the number of patients with cardiovascular and cerebrovascular diseases also growing, driving the market size of atovata calcium, Oxiracetam and other cardiovascular and cerebrovascular disease drugs to continue to expand, and the demand for ethyl 4-chloroacetoacetate products is also rising. According to the "2021-2025 China 4-chloroacetoacetate Industry Market Monitoring and Future Development Prospect Research Report", the demand for 4-chloroacetoacetate products in China in 2020 was 2782 tons, an increase of 8.2% year-on-year.
China's 4-chloroacetoacetate ethyl ester industry in the number of enterprises is small, the market product supply is tight, the overall competition in the industry is relatively moderate, the main enterprises are Anhui Jinhe Industrial Co., Ltd., Guangxi Jinyuan Biochemical Industry Co., Ltd., Suzhou Haobo Technology Co., Ltd., Jiangsu Hengan Chemical Co., Ltd. and so on. In recent years, affected by environmental protection policies, some enterprises in China's 4-chloroacetoacetate industry have withdrawn from the market, such as Changzhou Kefeng Chemical Co., Ltd., driven by the growth of downstream demand, some enterprises have put into production 4-chloroacetoacetate projects, such as Anhui Jinhe Industrial Co., Ltd., Guangxi Jinyuan Biochemical Industry Co., Ltd. and so on.
New Thinking Industry researchers said that the downstream drugs of ethyl 4-chloroacetoacetate such as atovata calcium, Oxiracetam, and cephalosporin have good market prospects, which will drive the rapid development of the 4-chloroacetoacetate market. It is estimated that ethyl 4-chloroacetoacetate in China is expected to reach 500 million yuan in 2025. In addition, Suzhou Haobo Technology Co., Ltd., Ningxia Hengti Technology Co., Ltd. and other companies have investment plans for the ethyl 4-chloroacetoacetate project, and the production capacity of 4-chloroacetoacetate in the east is also continuously transferred to the central and western regions, and is encouraged by the central and western policies, and the future development can be expected.